Notizie e Video - RECORDATI ORD

Recordati Rare Diseases announce today publication of the long-term outcomes from the open-label extension period of the Phase III LINC 3 study of Isturisa® in The European Journal of Endocrinology . 1 These data support the long-term utility of Isturisa® in the maintenance treatment of patients with Cushing’s disease and reinforce Isturisa as an effective and well-tolerated oral therapy. Isturisa® is indicated in the EU for the treatment of adult patients with endogenous Cushing’s...

Recordati Rare Diseases annonce la publication des résultats à long terme de la phase d’extension de l'étude de Phase III LINC 3 sur Isturisa® (osilodrostat) chez des patients atteints de la maladie de Cushing dans The European Journal of Endocrinology Recordati Rare Diseases annonce aujourd'hui la publication des résultats à long terme de la phase d’extension en ouvert de l'étude de Phase III LINC 3 évaluant Isturisa® dans The European Journal of Endocrinology . 1 Ces données...

Recordati Rare Diseases annonce la publication dans The Journal of Clinical Endocrinology & Metabolism de l’étude de Phase III LINC 4 confirmant l'efficacité et la tolérance d’Isturisa® (osilodrostat) chez les patients atteints de la maladie de Cushing. Recordati Rare Diseases annonce aujourd’hui la publication des résultats positifs de l’étude de Phase III LINC 4 d’Isturisa dans The Journal of Clinical Endocrinology & Metabolism . 1 Ces données renforcent la place d’Isturisa...

Recordati Rare Diseases announce today the publication of positive results from the Phase III LINC 4 study of Isturisa in The Journal of Clinical Endocrinology & Metabolism . 1 These data reinforce Isturisa as an effective and well-tolerated oral therapy for patients with Cushing’s disease. Isturisa is indicated in the EU for the treatment of adult patients with endogenous Cushing’s syndrome, 2 a rare and debilitating condition of hypercortisolism that is most commonly caused by a pituitary...

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICONFERMANO L’EFFICACIA E LA SICUREZZA DI ISTURISA® (OSILODROSTAT) PER IL TRATTAMENTO DELLA MALATTIA DI CUSHING Risultati statisticamente significativi emersi dallo studio pivotale di fase III LINC-4 dimostrano che Isturisa® (osilodrostat) consente di ottenere una normalizzazione rapida e duratura dei livelli medi di cortisolo libero urinario nella maggior parte dei...

Recordati Rare Diseases annuncia che risultati positivi provenienti dallo studio di fase III LINC 4 condotto su Isturisa® sono stati presentati il 22 marzo al congresso annuale de The Endocrine Society. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità del lettore e devono rinviare al testo in lingua originale, che è l'unico giuridicamente valido. Vedi la versione originale su...

Recordati Rare Diseases announces that positive results from the Phase III LINC 4 study of Isturisa® were presented on March 22 at The Endocrine Society’s Annual Meeting. 1 Results from LINC 4, the first Phase III study in patients with Cushing’s disease to include an upfront, double-blind, randomised, placebo-controlled period, demonstrated that Isturisa® provided rapid and sustained normalisation of mean urinary free cortisol (mUFC) levels. 1 Normalising mUFC levels represents an...

Recordati Rare Diseases : Les résultats positifs de l’étude LINC 4 de Phase III présentés aujourd’hui au congrès annuel de l’Endocrine Society confirment l’efficacité et la tolérance d’Isturisa® (osilodrostat) dans le traitement de la maladie de Cushing Recordati Rare Diseases annonce que les résultats positifs de l’étude LINC 4 de Phase III sur Isturisa® ont été présentés le 22 mars au congrès annuel de l’Endocrine Society. 1 Les résultats de LINC 4, première...

RECORDATI: RISULTATI PRELIMINARI 2020 CONFERMANO LA CONTINUA CRESCITA DEGLI UTILI OPERATIVI E UTILI NETTI. EBITDA +4,7% E UTILE NETTO RETTIFICATO +7,3% Ricavi netti consolidati € 1.448,9 milioni, -2,2% (+0,4% a tassi di cambio costanti). EBITDA (1) € 569,3 milioni, +4,7%. Utile operativo € 469,0 milioni, +0,8%. Utile netto €355,0 milioni, -3,8%; escludendo i benefici fiscali non ricorrenti legati al “Patent Box”, l’utile netto aumenta del +3,2%. Utile netto rettificato (2) €...

RECORDATI: OTTENUTA LICENZA PER LA COMMERCIALIZZAZIONE DI ELIGARD® IN EUROPA E ALTRI PAESI Milano, 29 gennaio 2021 - Recordati annuncia il perfezionamento di un accordo di Licenza e Fornitura con Tolmar International Ltd, per la commercializzazione di Eligard® (leuprorelin acetato), in Europa, Turchia, Russia e altri paesi. Eligard® è un medicinale indicato per il trattamento del cancro della prostata ormono-dipendente in stadio avanzato e per il trattamento del cancro della prostata...

RECORDATI: MARKET AUTHORIZATION APPLICATION FOR ARS-1 (EPINEPHRINE NASAL SPRAY) ACCEPTED BY EUROPEAN MEDICINES AGENCY Milan, 30 November 2020 – Recordati announces that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application (MAA) submission by ARS Pharmaceuticals for review of ARS-1 (known as Neffy TM in the USA), an epinephrine nasal spray for the emergency treatment of severe allergic reactions, including anaphylaxis. On 21 September 2020 Recordati announced...

RECORDATI: UTILI IN CRESCITA NEI PRIMI NOVE MESI DEL 2020. RICAVI -0,6%, EBITDA +7,1%, UTILE NETTO RETTIFICATO +12,3% Ricavi netti consolidati € 1.093,8 milioni, -0,6%, ovvero +1,1% a tassi di cambio costanti. EBITDA (1) € 438,8 milioni, +7,1%. Utile operativo € 364,0 milioni, +3,0%. Utile netto € 274,1 milioni, + 8,1%. Utile netto rettificato (2) € 317,5 milioni, +12,3%. Posizione finanziaria netta (3) : debito netto di € 845,9 milioni; € 902,7 milioni al 31 dicembre 2019....

RECORDATI: MERGER BY ABSORPTION OF FIMEI S.P.A. AND ROSSINI INVESTIMENTI S.P.A. INTO RECORDATI S.P.A. APPROVED Reverse merger by absorption of Fimei S.p.A. and Rossini Investimenti S.p.A. into Recordati S.p.A. approved by Board of Directors. Objective - shortened chain of control and simplified corporate governance structure. As a result of the merger, no variations of Recordati S.p.A.’s share capital and Articles of Association. As a result of the merger, the shareholdings in Recordati S.p.A....

ARS Pharmaceuticals and Recordati Announce Exclusive License for the Rights in Europe and additional countries for Neffy™ (ARS-1; epinephrine nasal spray) Agreement will give access to millions at risk for severe allergic reaction to new pain-free delivery method for epinephrine and will help in efforts to gain regulatory approval for ARS-1 (known as Neffy™ in the U.S.) around the world PR Newswire SAN DIEGO, Sept. 22, 2020 SAN DIEGO , Sept. 22, 2020 /PRNewswire/ -- ARS Pharmaceuticals (ARS)...

RECORDATI LICENSES AN INNOVATIVE EPINEPHRINE NASAL SPRAY IN DEVELOPMENT FOR ANAPHYLAXIS PREVENTION Milan, 21 September, 2020 - Recordati announces the signing of an exclusive license agreement with ARS Pharmaceuticals, a private U.S. company, for the commercialization in the European Union, Iceland, Liechtenstein, Norway, Switzerland, United Kingdom, Russia/CIS, Turkey, Middle East and French-speaking African countries, of ARS-1, an epinephrine nasal spray in late-stage development for the...

RECORDATI ANNOUNCES POSITIVE FIRST HALF 2020 RESULTS. REVENUES + 2.3 %, EBITDA + 11.4 %, ADJUSTED NET INCOME +16.8% Consolidated revenues € 760.2 million, +2.3%. EBITDA (1) € 311.1 million, +11.4% Operating income € 261.5 million, +7.8% Net income € € 196.9 million, + 13.0% Adjusted net income (2) € 225.6 million, +16.8% Net financial position (3) : net debt of € 922.4 million; € 902.7 million at 31 December 2019 Shareholders’ equity € 1,242.0 million Isturisa®...

Recordati Rare Diseases annonce ce jour que Lancet Diabetes & Endocrinology a publié les résultats positifs de l'étude pivot de phase III LINC-3 menée avec Isturisa®, récemment approuvé pour le traitement du syndrome de Cushing endogène chez l'adulte. Les patients atteints de la maladie de Cushing, la forme la plus courante du syndrome de Cushing endogène, présentent un risque accru de comorbidités, incluant notamment des maladies cardiovasculaires et métaboliques dues à des...

Recordati Rare Diseases announces today that Lancet Diabetes & Endocrinology has published positive results from the Phase III LINC-3 pivotal study of Isturisa®, recently approved for the treatment of endogenous Cushing’s syndrome in adults. Patients with Cushing’s disease, the most common form of endogenous Cushing’s syndrome, have an increased risk of significant comorbidities, including cardiovascular and cerebrovascular diseases as a result of excessive cortisol levels. 1 Data from...

Cortisol synthesis inhibitor osilodrostat (Isturisa®) is now available in Germany as of July 15, 2020, as a promising new therapy option for medical treatment of adult patients with endogenous Cushing’s syndrome (CS). 1,4 Isturisa® was approved by the European Commission on January 9, 2020. The approval of Isturisa® (osilodrostat) is based on the results of the pivotal phase III study, LINC-3, in which the efficacy and safety of osilodrostat in 137 patients with Cushing’s disease were...

Recordati Rare Diseases annonce ce jour des résultats positifs pour l’étude de Phase III LINC-4 évaluant Isturisa® (osilodrostat) dans le traitement de patients atteints de la maladie de Cushing pour lesquels une chirurgie hypophysaire n'est pas une option ou n'a pas été curative. Les données de l'étude LINC-4 démontrent qu'une proportion significativement plus importante de patients recevant Isturisa® a atteint un CLUm normal, objectif thérapeutique principal pour la maladie de...